Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer | OncLive

Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

September 26, 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Most of the approved drugs for patients with metastatic prostate cancer include immunotherapy, hormonal therapy, and chemotherapy. Precision medicine is the ability to use biomarkers for the optimal therapy, which makes treatment decisions easier for these patients, states Armstrong.

A blood test called the AR-V7 assay can help determine which patients will become resistant to enzalutamide (Xtandi) or abiraterone acetate (Zytiga), explains Armstrong.


x